{"abstract":"The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating amending an existing license to include a exclusive patent license to Molecular Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its principle place of business in West Chester, Pennsylvania, to practice the inventions embodied in the patent application listed in the SUPPLEMENTARY INFORMATION section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2019/06/17/2019-12708.html","cfr_references":[],"citation":"84 FR 28063","comment_url":null,"comments_close_on":"2019-07-02","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development July 2, 2019 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2019-12708","effective_on":null,"end_page":28063,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2019/06/17/2019-12708.xml","html_url":"https://www.federalregister.gov/documents/2019/06/17/2019-12708/prospective-grant-of-exclusive-patent-license-lutetium-177-radiotherapeutics-against","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2019-12708?publication_date=2019-06-17","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2019-06-17/2019-12708/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":322,"last_updated":"2026-10-24 12:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-06-17/pdf/2019-12708.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-12708.pdf?1560516325","publication_date":"2019-06-17","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2019/06/17/2019-12708.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T19:14:10Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":28063,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors","toc_doc":"Lutetium-177 Radiotherapeutics against Somatostatin-Receptor Expressing Neuroendocrine Tumors","toc_subject":"Prospective Grant of an Exclusive Patent License:","topics":[],"type":"Notice","volume":84}